PROGENRA, INC.
7Patents
6Active
7Granted
45Portfolio score
Filing activity: Jun 21, 2005 → Mar 2, 2018 · 2 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8680139B2 | Anti-neoplastic compounds, compositions and methods | Human Necessities | 8 | Active |
| US7842460B2 | Method for assessing proteolytic enzyme activity using ubiquitin fusion substrate | Physics | 7 | Expired |
| US8518660B2 | Di- and poly-ubiquitin deubiquitinase substrates and uses thereof | Chemistry; Metallurgy | 4 | Active |
| US8691958B2 | Methods and compositions for enhanced protein expression and purification | Chemistry; Metallurgy | 2 | Active |
| US9717717B1 | Methods of treating cancer through the inhibition of USP7 and immune system modulation | Human Necessities | 2 | Active |
| US11273154B2 | Azole compounds as ubiquitin-specific protease USP7 inhibitors | Chemistry; Metallurgy | 0 | Active |
| US10292973B2 | Covalent irreversible inhibitors of USP7 as anti-cancer agents | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.